• darkblurbg

    TARGETING THE UNDERLYING

    CAUSES OF DIABETES

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Calendar

 Dates for financial information and other events
Data pager
Data pager
12
April 25, 2019
Shareholders Meeting with Aktiespararna
Gullmarsgymnasiet, Lysekil
May 8, 2019
Global Forum on Vaccines and Vaccination
Valencia, Spain
May 29, 2019
Biotech Investorkonference Q2 2019
Copenhagen, Denmark
June 7 − June 11, 2019
American Diabetes Association’s 79th Scientific Sessions

We are seeing increased international visibility highlighting the work we are doing.

Ulf Hannelius
President and CEO, Diamyd Medical AB

THE COMPANY

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq Stockholm First North (ticker: DMYD B)


Read More
  • Diabetes

    10-20% of the more than 400 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.

  • Products

    The antigen-specific immunotherapy Diamyd® and the regenerative and immunomodulatory therapy Remygen® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.

  • Clinical Trials

    The efficacy of intralymphatic administration of Diamyd® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.